FDA Office of OTC Products acting director
Paula Botstein, MD, Office of Drug Evaluation I Deputy Director (Medical Affairs), will be interim director of the Office of OTC Products. Botstein will be working on a part-time basis in the new position. FDA is in the process of evaluating candidates for a permanent director of the OTC office. One of the candidates is Michael Weintraub, MD, an associate professor of community medicine, pharmacology, and medicine at the University of Rochester. The structure of the new office is awaiting final approval from FDA's Office of Management and Operations.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth